Entecavir Side Effects
Some side effects of entecavir may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to entecavir: oral solution, oral tablet
Along with its needed effects, entecavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking entecavir:Incidence not known
- Abdominal or stomach discomfort
- decreased appetite
- fast, shallow breathing
- general feeling of discomfort
- muscle pain or cramping
- right upper abdominal or stomach pain and fullness
- shortness of breath
- unusual tiredness or weakness
Some side effects of entecavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- Acid or sour stomach
- sleepiness or unusual drowsiness
- stomach discomfort, upset, or pain
- trouble sleeping
For Healthcare Professionals
Applies to entecavir: oral solution, oral tablet
The most common side effects reported in patients with chronic hepatitis B virus (HBV) infection and compensated liver disease during clinical trials have included headache, fatigue, dizziness, and nausea. One percent of patients discontinued treatment due to side effects or laboratory abnormalities (compared to 4% of lamivudine-treated patients).
The most common side effects reported in patients with chronic HBV infection and evidence of hepatic decompensation (n=102) through Week 48 of a study have included peripheral edema, ascites, pyrexia, hepatic encephalopathy, and upper respiratory infection. Eighteen percent of patients treated with entecavir died during the first 48 weeks of therapy (compared to 20% of adefovir-treated patients). The majority of deaths (11 of 18 entecavir-treated patients and 16 of 18 adefovir-treated patients) were due to liver-related causes such as hepatic failure, hepatic encephalopathy, hepatorenal syndrome, and upper gastrointestinal hemorrhage. Five percent of patients discontinued entecavir or adefovir due to a side effect through 48 weeks of therapy.
Hepatic side effects have included elevated ALT (greater than 10 times ULN and greater than 2 times baseline: 2%; greater than 5 times ULN: up to 12%) and total bilirubin (greater than 2.5 times ULN; up to 3%). Elevated AST and ALT flares have also been reported. Hepatic encephalopathy (10%) and deaths due to liver-related causes (such as hepatic failure, hepatic encephalopathy, and hepatorenal syndrome) have been reported in entecavir-treated patients with hepatic decompensation. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside/nucleotide analogs alone or in combination with other antiretroviral agents. Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of entecavir. Increased transaminases have been reported during postmarketing experience.
Posttreatment exacerbations of hepatitis or ALT flare, as defined by ALT greater than 10 times ULN and greater than 2 times baseline, have been reported in patients who discontinued treatment at or after 52 weeks after achieving a defined treatment response (nucleoside-naive HBeAg-positive, 2%; nucleoside-naive HBeAg-negative, 8%; lamivudine-refractory, 12%). The median time to exacerbation was 23 to 24 weeks. The rate may be higher in patients who discontinue entecavir without regard to treatment response.
Other side effects of moderate to severe intensity (Grade 2 to 4) have included fatigue (up to 3%). Fever, accidental injury, influenza, and back pain have also been reported. Peripheral edema (16%), ascites (15%), and pyrexia (14%) have been reported in entecavir-treated patients with hepatic decompensation.
Metabolic side effects have included elevated lipase (greater than or equal to 2.1 times ULN; 7%), fasting hyperglycemia (greater than 250 mg/dL; up to 3%), elevated alkaline phosphatase, and elevated amylase. Decreased blood bicarbonate has been reported in 2% of entecavir-treated patients with hepatic decompensation. Lactic acidosis has been reported during postmarketing experience.
Genitourinary side effects have included hematuria (Grade 3 to 4; 9%), glycosuria (Grade 3 to 4; 4%), and dysuria.
Renal side effects have included confirmed creatinine increases of 0.5 mg/dL or more (up to 2%). A confirmed increase in serum creatinine of 0.5 mg/dL (11%) and renal failure (less than 1%) have been reported in entecavir-treated patients with hepatic decompensation.
Respiratory side effects have included upper respiratory tract infection, cough, nasopharyngitis, and rhinitis. Upper respiratory infection has been reported in 10% of entecavir-treated patients with hepatic decompensation.
Gastrointestinal side effects of moderate to severe intensity (Grade 2 to 4) have included diarrhea (up to 1%), dyspepsia (up to 1%), nausea (less than 1%), and vomiting (less than 1%). Abdominal pain (unspecified) and upper abdominal pain have also been reported. Deaths due to gastrointestinal hemorrhage were reported in entecavir-treated patients with hepatic decompensation.
Oncologic side effects have included malignant neoplasms occurring at a rate of 8.4 per 1000 patient-years. Hepatocellular carcinoma has been reported in 6% of entecavir-treated patients with hepatic decompensation.
Nervous system side effects of moderate to severe intensity (Grade 2 to 4) have included headache (up to 4%), dizziness (less than 1%), and somnolence (less than 1%).
Hematologic side effects have included decreased albumin (less than 2.5 g/dL) and platelets (less than 50,000/mm3) in less than 1% of patients.
Immunologic side effects have included anaphylactoid reaction during postmarketing experience.
Psychiatric side effects of moderate to severe intensity (Grade 2 to 4) have included insomnia (less than 1%).
Musculoskeletal side effects have included arthralgia and myalgia.
Dermatologic side effects have included erythema. Rash and alopecia have been reported during postmarketing experience.
Hypersensitivity side effects have included photosensitivity with lethargy in at least one patient, which resolved after stopping entecavir.
More about entecavir
- Other brands: Baraclude
Compare with other treatments for:
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.